# Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

> **NCT00662506** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 46 (actual)

## Conditions studied

- Adult Giant Cell Glioblastoma
- Adult Glioblastoma
- Adult Gliosarcoma

## Interventions

- **DRUG:** Cediranib Maleate
- **PROCEDURE:** Diffusion Tensor Imaging
- **PROCEDURE:** Diffusion Weighted Imaging
- **PROCEDURE:** Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- **RADIATION:** Fludeoxyglucose F-18
- **RADIATION:** Intensity-Modulated Radiation Therapy
- **OTHER:** Laboratory Biomarker Analysis
- **PROCEDURE:** Perfusion Magnetic Resonance Imaging
- **PROCEDURE:** Positron Emission Tomography
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT00662506
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2023-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00662506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00662506, "Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00662506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*